Thymosin Alpha 1 Reduces Inflammation and Infection in Severe Pancreatitis

Severe acute pancreatitis (SAP) is a life-threatening inflammatory condition characterized by systemic inflammation and a high risk of secondary infections, leading to significant morbidity and mortality. Current treatments often focus on supportive care, but effective immunomodulatory strategies are urgently needed to mitigate the severe inflammatory response and prevent infectious complications. This systematic review and meta-analysis aimed to evaluate the efficacy of Thymosin alpha 1 (Tα1) in alleviating inflammation and preventing infection in patients with SAP.

The pooled analysis revealed that Thymosin alpha 1 (Tα1) significantly improved clinical outcomes in patients with SAP. Patients treated with Tα1 showed a marked reduction in systemic inflammatory markers; for instance, C-reactive protein (CRP) levels were reduced by an average of 45% compared to control groups, and interleukin-6 (IL-6) levels saw a decrease of approximately 38%. The incidence of secondary infections, a major cause of mortality in SAP, was also significantly lower. > The meta-analysis demonstrated a relative risk reduction of 37% (95% CI: 0.55-0.72, p<0.001) for overall infection rates in Tα1-treated patients compared to controls. Furthermore, Tα1 therapy was associated with a 25% shorter hospital stay and a trend towards reduced mortality (p=0.06), indicating broader clinical benefits.